Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Am J Trop Med Hyg ; 101(1): 101-107, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31094311

RESUMO

Cutaneous leishmaniasis (CL) remains one of the world's most prevalent neglected diseases, particularly in developing countries. Identification of the involved Leishmania species is an important step in the diagnosis and case management process. In this study, we tested simple, rapid, and highly sensitive loop-mediated isothermal amplification (LAMP) assays for Leishmania DNA species-specific detection from cutaneous lesions. Two LAMP assays, targeting cysteine protease B (cpb) gene, were developed to detect and identify Leishmania major and Leishmania tropica species. Loop-mediated isothermal amplification specificity was examined using DNA samples from other Leishmania species and Trypanosoma species. No cross-reactions were detected. The developed LAMP assays exhibited sensitivity with a detection limit of 20 fg and 200 fg for L. major and L. tropica, respectively. Both tests were applied on clinical samples of CL suspected patients living in endemic Tunisian regions and compared with kinetoplast DNA quantitative PCR (qPCR), microscopic, and conventional cpb-based polymerase chain reaction (PCR) assays. Our LAMP tests were able to discriminate between L. major and L. tropica species and showed a sensitivity of 84% and a specificity of 100%. However, when compared with the performance of the diagnostic tests with latent class analysis (LCA), our LAMP assays show a sensitivity of 100%. These assays can be used as a first-line molecular test for early diagnosis and prompt management of CL cases in public health programs.


Assuntos
Leishmania major/genética , Leishmania tropica/genética , Leishmaniose Cutânea/diagnóstico , Leishmaniose Cutânea/epidemiologia , Humanos , Leishmaniose Cutânea/parasitologia , Doenças Negligenciadas/diagnóstico , Doenças Negligenciadas/epidemiologia , Doenças Negligenciadas/parasitologia , Técnicas de Amplificação de Ácido Nucleico , Especificidade da Espécie , Tunísia/epidemiologia
2.
Artigo em Inglês | MEDLINE | ID: mdl-28137819

RESUMO

In any drug discovery and development effort, a reduction in the time of the lead optimization cycle is critical to decrease the time to license and reduce costs. In addition, ethical guidelines call for the more ethical use of animals to minimize the number of animals used and decrease their suffering. Therefore, any effort to develop drugs to treat cutaneous leishmaniasis requires multiple tiers of in vivo testing that start with higher-throughput efficacy assessments and progress to lower-throughput models with the most clinical relevance. Here, we describe the validation of a high-throughput, first-tier, noninvasive model of lesion suppression that uses an in vivo optical imaging technology for the initial screening of compounds. A strong correlation between luciferase activity and the parasite load at up to 18 days postinfection was found. This correlation allows the direct assessment of the effects of drug treatment on parasite burden. We demonstrate that there is a strong correlation between drug efficacy measured on day 18 postinfection and the suppression of lesion size by day 60 postinfection, which allows us to reach an accurate conclusion on drug efficacy in only 18 days. Compounds demonstrating a significant reduction in the bioluminescence signal compared to that in control animals can be tested in lower-throughput, more definitive tests of lesion cure in BALB/c mice and Golden Syrian hamsters (GSH) using Old World and New World parasites.


Assuntos
Antiprotozoários/farmacologia , Ensaios de Triagem em Larga Escala , Leishmania major/efeitos dos fármacos , Leishmaniose Cutânea/tratamento farmacológico , Organismos Geneticamente Modificados , Anfotericina B/farmacologia , Animais , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos/economia , Avaliação Pré-Clínica de Medicamentos/métodos , Feminino , Luciferina de Vaga-Lumes/administração & dosagem , Fluconazol/farmacologia , Genes Reporter , Leishmania major/genética , Leishmania major/crescimento & desenvolvimento , Leishmaniose Cutânea/parasitologia , Leishmaniose Cutânea/patologia , Luciferases/genética , Luciferases/metabolismo , Medições Luminescentes , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Meglumina/farmacologia , Antimoniato de Meglumina , Mesocricetus , Camundongos , Camundongos Endogâmicos BALB C , Ofloxacino/farmacologia , Imagem Óptica , Compostos Organometálicos/farmacologia , Triazóis/farmacologia
3.
Korean J Parasitol ; 53(4): 385-94, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26323836

RESUMO

Leishmaniasis is a worldwide uncontrolled parasitic disease due to the lack of effective drug and vaccine. To speed up effective drug development, we need powerful methods to rapidly assess drug effectiveness against the intracellular form of Leishmania in high throughput assays. Reporter gene technology has proven to be an excellent tool for drug screening in vitro. The effects of reporter proteins on parasite infectivity should be identified both in vitro and in vivo. In this research, we initially compared the infectivity rate of recombinant Leishmania major expressing stably enhanced green fluorescent protein (EGFP) alone or EGFP-luciferase (EGFP-LUC) with the wild-type strain. Next, we evaluated the sensitivity of these parasites to amphotericin B (AmB) as a standard drug in 2 parasitic phases, promastigote and amastigote. This comparison was made by MTT and nitric oxide (NO) assay and by quantifying the specific signals derived from reporter genes like EGFP intensity and luciferase activity. To study the amastigote form, both B10R and THP-1 macrophage cell lines were infected in the stationary phase and were exposed to AmB at different time points. Our results clearly revealed that the 3 parasite lines had similar in vitro infectivity rates with comparable parasite-induced levels of NO following interferon-γ/lipopolysaccharide induction. Based on our results we proposed the more reporter gene, the faster and more sensitive evaluation of the drug efficiency.


Assuntos
Anfotericina B/farmacologia , Antiprotozoários/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , Proteínas de Fluorescência Verde/metabolismo , Leishmania major/efeitos dos fármacos , Leishmaniose Cutânea/parasitologia , Luciferases/metabolismo , Animais , Avaliação Pré-Clínica de Medicamentos/instrumentação , Feminino , Expressão Gênica , Genes Reporter , Proteínas de Fluorescência Verde/genética , Humanos , Leishmania major/genética , Leishmania major/crescimento & desenvolvimento , Leishmania major/fisiologia , Luciferases/genética , Camundongos
4.
Int J Parasitol ; 36(14): 1499-514, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17011565

RESUMO

The single mitochondrion of kinetoplastids divides in synchrony with the nucleus and plays a crucial role in cell division. However, despite its importance and potential as a drug target, the mechanism of mitochondrial division and segregation and the molecules involved are only partly understood. In our quest to identify novel mitochondrial proteins in Leishmania, we constructed a hidden Markov model from the targeting motifs of known mitochondrial proteins as a tool to search the Leishmania major genome. We show here that one of the 17 proteins of unknown function that we identified, designated mitochondrial protein X (MIX), is an oligomeric protein probably located in the inner membrane and expressed throughout the Leishmania life cycle. The MIX gene appears to be essential. Moreover, even deletion of one allele from L. major led to abnormalities in cell morphology, mitochondrial segregation and, importantly, to loss of virulence. MIX is unique to kinetoplastids but its heterologous expression in Saccharomyces cerevisiae produced defects in mitochondrial morphology. Our data show that a number of mitochondrial proteins are unique to kinetoplastids and some, like MIX, play a central role in mitochondrial segregation and cell division, as well as virulence.


Assuntos
Leishmania major/genética , Proteínas Mitocondriais/genética , Sequência de Aminoácidos , Animais , Divisão Celular/genética , Deleção de Genes , Genoma de Protozoário/genética , Kinetoplastida/química , Kinetoplastida/genética , Kinetoplastida/ultraestrutura , Leishmania major/química , Leishmania major/ultraestrutura , Leishmaniose Cutânea/genética , Leishmaniose Cutânea/metabolismo , Estágios do Ciclo de Vida , Cadeias de Markov , Camundongos , Camundongos Endogâmicos BALB C , Microscopia Eletrônica de Varredura/métodos , Mitocôndrias/química , Mitocôndrias/genética , Membranas Mitocondriais/química , Saccharomyces cerevisiae/química , Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/química , Proteínas de Saccharomyces cerevisiae/genética , Trypanosoma/química , Trypanosoma/genética , Trypanosoma/ultraestrutura , Virulência/genética
6.
Parasite Immunol ; 22(5): 231-7, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10792762

RESUMO

Infection of mice with Leishmania major has been used both as a model for the cutaneous disease in humans and as a model for the more general control and function of helper T cells in immunity. In both cases, disease patterns and disease progression have been assessed by two complementary methods, lesion size and parasite burden in the draining lymph nodes. We propose a much improved method for the graphical representation of lesion development which conveys more information with better accuracy. We also describe a polymerase chain reaction method for determining parasite burden, which is faster and allows the analysis of larger numbers of experimental animals than the current limiting dilution analysis. Moreover, these methods are equally applicable to other infectious diseases, an obvious one being schistosomiasis.


Assuntos
DNA de Protozoário/análise , Leishmania major/isolamento & purificação , Leishmaniose Cutânea/patologia , Leishmaniose Cutânea/parasitologia , Linfonodos/parasitologia , Animais , Modelos Animais de Doenças , Progressão da Doença , Leishmania major/genética , Leishmaniose Cutânea/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Reação em Cadeia da Polimerase/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA